RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación
Artículo científico (JournalArticle)
NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC
[EN] Lung cancer is the deadliest neoplasia worldwide. Despite the availability of targeted therapies like tyrosine kinase inhibitors (TKIs) for EGFR-driven tumours in Non-Small Cell Lung Cancer (NSCLC), drug resistance remains a major factor that dramatically cuts life expectancy. Here we identify how increased expression of nicotinamide N-methyltransferase (NNMT) in TKI-resistant cancer cells diverts nicotinamide to synthesise 1-Methylnicotinamide (1-MNA) and lowers NAD+ levels that generates a druggable nicotinamide phosphoribosyltransferase (NAMPT) metabolic vulnerability. We also report that high blood levels of 1-MNA, the byproduct of NNMT activity, are significantly associated with lower survival rates in EGFR TKI-treated NSCLC patients. Taken together, our findings describe a new and highly specific non-genetic metabolic synthetic lethality for mesenchymal-like tumours, which exposes NAMPT as an in vivo druggable target and establishes 1-MNA as a novel liquid biopsy biomarker to predict and monitor EGFR TKI resistance in NSCLC., This work is supported by the Spanish Ministry of Science, Innovation and Universities (SAF2017-85352 and PID2020-119426RB-I00) and the Domingo Martinez Foundation to J. Carretero; NIH grant CA230778 and DoD CDMRP LCRP HT9425-23-1-0486, HT9425-23-1-0713, and HT9425-23-1-0497 to T. Shimamura; the European Regional Development Fund, the Carlos III Institute of Health of the Spanish Ministry of Science, Innovation and Universities (PI23/01369 and PI20/00580) to A. Lahoz; DoD CDMRP LCRP W81XWH-22-1-0023 to I. Pulido; and the Mansueto Lung Research Fund to Malek Massad. Part of the equipment used in this work was cofunded by the Generalitat Valenciana and the European Regional Development Fund (FEDER of the Comunitat Valenciana 2014-2020) . We gratefully acknowledge the support of the INCLIVA BioBank (PT17/0015/0049; B.000768 ISCIII) as part of the Valencian Biobanking Network and the Spanish National Biobanks Network. We thank Dr. Enrico Benedetti, Dr. Ajay Rana, and the Department of Surgery at the University of Illinois, Chicago, and Dr. Roque Bort from the La Fe Hospital for their help and support.
Proyecto:
ISCIII / Plan Estatal de Investigación Científica PI23/01369
,
Instituto de Salud Carlos III / Técnica y de Innovación para el periodo
2021-2023 PI20/00580
,
Instituto de Salud Carlos III / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) CB16/12/00350
,
Instituto de Salud Carlos III B.000768
,
Instituto de Salud Carlos III PT17/0015/0049
,
Ministerio de Ciencia SAF2017-85352
,
Innovación y Universidades LCRP W81XWH-22-1-0023
,
U.S. Department of Health and Human Services CA230778
,
U.S. Department of Health and Human Services LCRP HT9425-23-1-0486
,
U.S. Department of Health and Human Services HT9425-23-1-0713
,
U.S. Department of Health and Human Services HT9425-23-1-0497
,
U.S. Department of Health and Human Services PID2020-119426RB-I00